2023
Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status
Rabe K, Pavord I, Busse W, Chupp G, Izuhara K, Altincatal A, Gall R, Pandit‐Abid N, Deniz Y, Rowe P, Jacob‐Nara J, Radwan A. Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status. Allergy 2023, 78: 2148-2156. PMID: 37073882, DOI: 10.1111/all.15747.Peer-Reviewed Original ResearchConceptsParent study baselineType 2 inflammationPre-bronchodilator FEVAsthma exacerbation rateType 2 asthmaAllergic asthmaExacerbation rateSevere asthma exacerbation ratesSevere type 2 asthmaAsthma Control Questionnaire scoreACQ-5 scoresReduced exacerbation ratesLong-term outcomesLong-term treatmentAllergic statusDupilumab efficacyGINA guidelinesQUEST studyWeek 96Asthma controlUncontrolled asthmaWeek 48Allergic phenotypeLung functionQuestionnaire scores
2004
Asthma: Mechanisms of Disease Persistence and Progression
Cohn L, Elias JA, Chupp GL. Asthma: Mechanisms of Disease Persistence and Progression. Annual Review Of Immunology 2004, 22: 789-815. PMID: 15032597, DOI: 10.1146/annurev.immunol.22.012703.104716.BooksConceptsIL-13Key effector cytokineAnti-inflammatory therapyIL-13 productionProduction of chemokinesProgression of diseaseAirway fibrosisAllergic asthmaAirway remodelingEffector cytokinesEosinophilic inflammationPersistent diseaseTh2 cytokinesEpithelial damageDisease progressionInflammatory responseTh2 cellsMucus productionSmooth muscleBronchial airwaysMatrix metalloproteinasesAnimal dataAsthmaDisease persistenceInflammation